Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate that the efficacy of Secukinumab 150 mg s.c. (Secukinumab from week 0 with NSAID tapering allowed from week 4; “delayed tapering”) at Week 12 is superior to placebo based on the proportion of patients achieving an ASAS20 response.
Critère d'inclusion
- Ankylosing spondylitis